OptimizeRx (OPRX) Q2 2024 earnings summary

Executive summary

• Q2 2024 revenue reached $18.8 million, up 36% year-over-year, driven by DAAP sales growth and the Medicx Health acquisition, with gross margin improving to 62.2% and positive cash flow from operations.

• Net loss for Q2 2024 was $4.0 million ($0.22 per share), slightly improved from Q2 2023, while non-GAAP net income was $0.3 million and Adjusted EBITDA turned positive at $0.5 million.

• Strong DAAP adoption with 17 deals closed in H1 2024, including eight in Q2, and significant client interest among top pharma clients.

• Integration of Medicx progressing well, with enhanced sales team and cross-sell opportunities expected to drive growth in the second half.

• Operating expenses rose 22% year-over-year in Q2 2024, mainly due to increased headcount and integration costs from the Medicx Health acquisition.

Financial highlights

• Q2 2024 net revenue was $18.8 million (+36% YoY); gross profit was $11.7 million (62.2% margin); net loss was $4.0 million ($0.22/share); non-GAAP net income was $0.3 million; Adjusted EBITDA was $0.5 million.

• Cash and equivalents at June 30, 2024, totaled $15.0 million; net cash from operations for H1 2024 was $2.9 million.

• Debt principal stands at $37.3 million after repayments since the Medicx acquisition.

• Net revenue retention rate improved to 124% from 89% in Q2 2023.

• Revenue per FTE rose to $658,000 from $565,000 year-over-year.

Outlook and guidance

• High conviction in achieving full-year revenue guidance, with 80% visibility and $15 million in incremental sales needed for the second half to meet consensus.

• Expectation that delayed $6 million DAAP deal will close and convert to revenue in H2 2024.

• 2024 full-year guidance reiterated: revenue expected to be at least $100 million and Adjusted EBITDA at least $11 million.

• Management expects funds from operations and existing cash to be sufficient for the next 12 months.

• Seasonality expected, with 25–30% of annual revenue in Q3 and the remainder in Q4.